Cardiol Therapeutics Inc. Class A Common Shares (CRDL) is a publicly traded Healthcare sector company. As of May 21, 2026, CRDL trades at $1.31 with a market cap of $147.55M and a P/E ratio of 0.00. CRDL moved +3.17% today. Year to date, CRDL is +30.00%; over the trailing twelve months it is +16.07%. Its 52-week range spans $0.77 to $2.24. Analyst consensus is buy with an average price target of $8.50. Rallies surfaces CRDL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Hedge funds tracked by Rallies that own CRDL include Citadel Advisors, Two Sigma, and Two Sigma. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Cardiol Therapeutics Inc. Class A Common Shares.
| Metric | Value |
|---|---|
| Price | $1.31 |
| Market Cap | $147.55M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.24 |
| 52-Week Low | $0.77 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
2 analysts cover CRDL: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $8.50.